Skip to main content

Advertisement

ADVERTISEMENT

News

News
05/14/2024

Stephanie Holland 

Stephanie Holland 
According to long-term results from the RADICALS-RT study, adjuvant radiotherapy does not meaningfully improve disease control and increases the risk of urinary and bowel morbidities among patients with prostate cancer at risk of recurrence...
According to long-term results from the RADICALS-RT study, adjuvant radiotherapy does not meaningfully improve disease control and increases the risk of urinary and bowel morbidities among patients with prostate cancer at risk of recurrence...
According to long-term results...
05/14/2024
Oncology
News
04/03/2024

Stephanie Holland 

Stephanie Holland 
According to results from the phase 3 NRG-GU003 trial, hypofractionated postprostatectomy radiotherapy did not significantly increase the likeliness of experiencing patient-reported genitourinary or gastrointestinal symptoms 1 to 2 years post...
According to results from the phase 3 NRG-GU003 trial, hypofractionated postprostatectomy radiotherapy did not significantly increase the likeliness of experiencing patient-reported genitourinary or gastrointestinal symptoms 1 to 2 years post...
According to results from the...
04/03/2024
Oncology
News
02/23/2024

Allison Casey 

Allison Casey 
According to interim results from a phase 3 study, the addition of apalutamide to androgen deprivation therapy showed a statistically and clinically significant improvement of PSA progression-free survival among patients with high-risk...
According to interim results from a phase 3 study, the addition of apalutamide to androgen deprivation therapy showed a statistically and clinically significant improvement of PSA progression-free survival among patients with high-risk...
According to interim results...
02/23/2024
Oncology

Advertisement

News
02/23/2024

Allison Casey 

Allison Casey 
According to interim results from a phase 3 study, the addition of apalutamide to androgen deprivation therapy showed a statistically and clinically significant improvement of PSA progression-free survival among patients with high-risk...
According to interim results from a phase 3 study, the addition of apalutamide to androgen deprivation therapy showed a statistically and clinically significant improvement of PSA progression-free survival among patients with high-risk...
According to interim results...
02/23/2024
Oncology
Conference Coverage
01/25/2024

Stephanie Holland 

Stephanie Holland 
Results from the ongoing phase 3 CONTACT-2 trial demonstrated that cabozantinib plus atezolizumab significantly improved rPFS compared to abiraterone plus prednisone or enzalutamide among patients with metastatic castration-resistant prostate...
Results from the ongoing phase 3 CONTACT-2 trial demonstrated that cabozantinib plus atezolizumab significantly improved rPFS compared to abiraterone plus prednisone or enzalutamide among patients with metastatic castration-resistant prostate...
Results from the ongoing phase 3...
01/25/2024
Oncology
Conference Coverage
01/25/2024

Stephanie Holland 

Stephanie Holland 
Results from the ongoing phase 3 CONTACT-2 trial demonstrated that cabozantinib plus atezolizumab significantly improved rPFS compared to abiraterone plus prednisone or enzalutamide among patients with metastatic castration-resistant prostate...
Results from the ongoing phase 3 CONTACT-2 trial demonstrated that cabozantinib plus atezolizumab significantly improved rPFS compared to abiraterone plus prednisone or enzalutamide among patients with metastatic castration-resistant prostate...
Results from the ongoing phase 3...
01/25/2024
Oncology

Advertisement

Conference Coverage
01/25/2024
Allison Casey
According to a phase 3 trial, dose-escalated radiotherapy combined with long-term androgen deprivation therapy improved the survival outcomes, without increasing toxicities, among patients with high-risk prostate cancer.
According to a phase 3 trial, dose-escalated radiotherapy combined with long-term androgen deprivation therapy improved the survival outcomes, without increasing toxicities, among patients with high-risk prostate cancer.
According to a phase 3 trial,...
01/25/2024
Oncology
News
01/12/2024
Allison Casey
In a retrospective cohort study, the PRIMARY score was found to be superior to MRI in detecting clinically significant prostate cancer, demonstrating added diagnostic value in patients with negative or equivocal MRI results.
In a retrospective cohort study, the PRIMARY score was found to be superior to MRI in detecting clinically significant prostate cancer, demonstrating added diagnostic value in patients with negative or equivocal MRI results.
In a retrospective cohort study,...
01/12/2024
Oncology
News
01/12/2024
Allison Casey
According to a retrospective study, actinium-255-PSMA radioligand therapy showed a substantial antitumor effect among patients with metastatic castration-resistant prostate cancer.
According to a retrospective study, actinium-255-PSMA radioligand therapy showed a substantial antitumor effect among patients with metastatic castration-resistant prostate cancer.
According to a retrospective...
01/12/2024
Oncology

Advertisement

News
01/05/2024
Allison Casey
A real world study found triplet therapy to be an effective and tolerable treatment option for patients with metastatic hormone-sensitive prostate cancer.
A real world study found triplet therapy to be an effective and tolerable treatment option for patients with metastatic hormone-sensitive prostate cancer.
A real world study found triplet...
01/05/2024
Oncology

Advertisement